Evidence map›Paper›PMID 35503027›Full record

ArticleBlood advances2022

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients.

Adam Cuker, Eric K Tseng, Robby Nieuwlaat, Pantep Angchaisuksiri, Clifton Blair, Kathryn Dane, Maria T DeSancho, David Diuguid, Daniel O Griffin, Susan R Kahn and 36 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 3 pooled it
14.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. COVID-19 therapeutics.Clinical microbiology reviews · 2024
    Review
  11. Review
  12. Article
  13. Article
  14. AMMI Canada Practice Point: Updated recommendations for treatment of adults with symptomatic COVID-19 in 2023-2024.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2024
    Article
  15. Article
  16. Review
  17. Article
  18. Anticoagulant therapy in COVID-19: A narrative review.Clinical and translational science · 2023
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

46 authors at 20 institutions in 11 countries.

Adam CukerDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-3595-5697
Eric K TsengDivision of Hematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.ORCID 0000-0003-2745-8057
Robby NieuwlaatDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.
Pantep AngchaisuksiriDivision of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Clifton BlairUnion, NJ.
Kathryn DaneDepartment of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD.
Maria T DeSanchoDivision of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY.
David DiuguidDivision of Hematology, and.
Daniel O GriffinDivision of Infectious Diseases, College of Physicians & Surgeons of Columbia University, New York, NY.ORCID 0000-0001-5853-6906
Susan R KahnDepartment of Medicine, McGill University, Montreal, QC, Canada.
Frederikus A KlokDepartment of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0001-9961-0754
Alfred Ian LeeSection of Hematology, Yale School of Medicine, New Haven, CT.ORCID 0000-0002-5968-3948
Ignacio NeumannDepartment of Internal Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Ashok PaiDivision of Hematology & Oncology, Kaiser Permanente, Oakland/Richmond, CA.
Marc RighiniDivision of Angiology and Hemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
Kristen M SanfilippoWashington University School of Medicine St. Louis, St. Louis, MO.ORCID 0000-0002-0433-7845
Deborah M SiegalDepartment of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.ORCID 0000-0003-3806-3245
Mike SkaraCottage Grove, MN.
Deirdra R TerrellDepartment of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK.ORCID 0000-0003-0794-5851
Kamshad TouriToronto, ON, Canada.
Elie A AklDepartment of Internal Medicine, American University of Beirut, Beirut, Lebanon.ORCID 0000-0002-3444-8618
Reyad Al JabiriUniversity of Jordan, Amman, Jordan.
Yazan Al JabiriLincoln Medical Center, Bronx, NY.
Angela M BarbaraDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.
Antonio BognanniDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0003-0128-903X
Mary BoulosDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0001-5046-598X
Romina Brignardello-PetersenDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-6010-9900
Rana CharideClinical Research Institute, American University of Beirut, Beirut, Lebanon.ORCID 0000-0001-5512-0091
Luis E Colunga-LozanoDepartment of Clinical Medicine, Health Science Center, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.ORCID 0000-0001-7737-4914
Karin DearnessLibrary Services, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.ORCID 0000-0002-6854-0156
Andrea J DarziDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-2498-1697
Heba HusseinOral Medicine and Periodontology Department, Faculty of Dentistry, Cairo University, Cairo, Egypt.ORCID 0000-0001-6042-361X
Samer G KaramDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-5167-4246
Razan MansourOffice of Scientific Affairs and Research, King Hussein Cancer Center, Amman, Jordan.ORCID 0000-0002-7719-9068
Gian Paolo MorganoDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0001-7577-7963
Rami Z MorsiDepartment of Neurology, University of Chicago, Chicago, IL.ORCID 0000-0003-2131-3711
Giovanna Muti-SchünemannDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.
Menatalla K NadimDepartment of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.ORCID 0000-0003-1506-3613
Binu A PhilipDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.
Yuan QiuDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-9572-9106
Yetiani Roldan BenitezDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.
Adrienne StevensDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-6257-4806
Karla SoloDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0001-6134-9140
Wojtek WierciochDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0001-6576-1650
Reem A MustafaDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-2091-0875
Holger J SchünemannDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0003-3211-8479
Cochrane · CAAmerican University of Beirut · LBAin Shams University · EGCairo University · EGJohns Hopkins Hospital · USKaiser Permanente Oakland Medical Center · USKing Hussein Cancer Center · JOLeiden University Medical Center · NLLincoln Medical Center · USMahidol University · THMcGill University · CANewYork–Presbyterian Hospital · USPontificia Universidad Católica de Chile · CLSt. Joseph’s Healthcare Hamilton · CASt. Michael's Hospital · CAUnitedHealth Group (United States) · USUniversidad de Guadalajara · MXUniversity Hospital of Geneva · CHUniversity of Chicago · USUniversity of Freiburg · DE

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Life after Recovery in Adult Thrombotic Thrombocytopenic Purpura (TTP): Let's Hear It from the SurvivorsK01HL135466 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI TERRELL, DEIRDRA R · 2017 to 2021
$687k
NCATS NIH HHS UL1 TR001863NHLBI NIH HHS K01 HL135466
6 · The paper itself

Abstract

backgroundCOVID-19-related acute illness is associated with an increased risk of venous thromboembolism (VTE).

objectiveThese evidence-based guidelines from the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in making decisions about the use of anticoagulation in patients with COVID-19.

methodsASH formed a multidisciplinary guideline panel that included patient representatives and applied strategies to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process and performed systematic evidence reviews (through November 2021). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess evidence and make recommendations, which were subject to public comment. This is an update to guidelines published in February 2021 as part of the living phase of these guidelines.

resultsThe panel made one additional recommendation. The panel issued a conditional recommendation in favor of therapeutic-intensity over prophylactic-intensity anticoagulation in patients with COVID-19-related acute illness who do not have suspected or confirmed VTE. The panel emphasized the need for an individualized assessment of risk of thrombosis and bleeding. The panel also noted that heparin (unfractionated or low molecular weight) may be preferred because of a preponderance of evidence with this class of anticoagulants.

conclusionThis conditional recommendation was based on very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials comparing different intensities of anticoagulation in patients with COVID-19-related acute illness.

Indexed as

COVID-19HematologyVenous ThromboembolismAcute DiseaseAnticoagulantsHumansUnited StatesAnticoagulants

Identifiers

PMID35503027
PMCPMC9068240
OpenAlexW4225308126

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.